MILAN, Italy and NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) — Genenta Science, a clinical-stage biotechnology firm pioneering the event of a hematopoietic stem cell gene remedy for most cancers (Temferon™), publicizes that Richard Slansky is appointed as Chief Financial Officer (“CFO”) and proposes Anthony Marucci as impartial member of the Board of Directors. The information follows the announcement of Stephen Squinto, PhD, as Chairman final November. Both Board appointments will likely be efficient following their approval on the Genenta Shareholders’ Meeting on May 20, 2021.
Pierluigi Paracchi, CEO at Genenta Science, mentioned: “I am delighted to welcome Richard and Anthony to Genenta, as we continue to enhance our management team and Board. They both have impressive backgrounds in life science and strategic business growth. Richard is a deeply experienced finance executive, who has a successful track record in raising funds and managing private and public pre-revenue companies. He will bring significant healthcare and management expertise to our team. Anthony will provide new perspectives as an entrepreneur in the immunotherapy areas and his advice, based on extensive business acumen and industry knowledge, will be invaluable as we further develop Genenta. I look forward to working closely with both of our new colleagues.”
Richard Slansky is an skilled senior govt who has intensive monetary management expertise with P&L accountability in public and personal life sciences firms for over 30 years. He was CFO of Biological Dynamics, a non-public firm creating a platform know-how to isolate DNA, RNA, proteins and exosomes from blood, plasma or serum, from 2018-2020. He was beforehand CFO of OncoSec Medical, a public firm the place he managed three registered direct public choices, and various different firms within the healthcare and know-how industries. He holds an MBA from the University of Arizona, a BS from the Wharton School on the University of Pennsylvania and serves on the Board of Directors of a number of personal firms.
Anthony Marucci is a seasoned life sciences and public firm chief who has raised $1.7 billion in capital in a number of organizations over his 30 years’ expertise. He is presently President and CEO of Celldex Therapeutics, the corporate he co-founded in 2004 and which develops focused therapeutics, together with immunotherapies and different focused biologics. Prior to founding Celldex, he was Treasurer at Medarex, from which Celldex was spun out, and he holds an MBA from Columbia University and a MHL from Brown University. His appointment to the Board of Directors will likely be efficient with the approval of the Genenta Shareholders’ Meeting.
Richard Slansky mentioned: “I am excited to be joining Genenta at this critical point for the company as it advances the novel immuno-gene therapy Temferon through clinical development. Temferon has the potential to revolutionize the way we address a broad range of tumors and I look forward to working with the talented and dynamic team at Genenta to bring it toward market and help patients in desperate need.”
Anthony Marucci mentioned: “It is an honor to be asked to join the Board of Directors of Genenta and play a role in its pioneering scientific work. With a strong and knowledgeable team in place and an exciting product, Temferon, in development, I am confident in our ability to transform the treatment options for patients suffering from devastating cancers.”
About Genenta Science
Genenta (www.genenta.com) is a clinical-stage biotechnology firm pioneering the event of proprietary hematopoietic stem cell gene therapies for the remedy of a wide range of cancers. Temferon™ is predicated on ex-vivo gene switch into autologous hematopoietic stem/progenitor cells (HSPCs) to ship immunomodulatory molecules instantly through tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes – TEMs). Temferon™, which is underneath investigation in a Phase I/IIa medical trial in newly identified Glioblastoma Multiforme sufferers, will not be restricted to pre-selected tumor antigens nor kind and might attain strong tumors, one of many foremost unresolved problem in immuno-oncology. Based in Milan, Italy, and New York, USA, Genenta has raised greater than €33.6 million (~$40 million) in three separate rounds of financing.
|Investor Relator – LifeSci Advisors:
Mary-Ann Chang, CFA
+44 7483 28.48.53
|Genenta Media/Investor Contact:
Valentina Brambilla, MSc
+39 388 789.15.41
|GENENTA SCIENCE Srl
OSR – DiBit 1 – Via Olgettina, 58 – 20132 Milan (Italy)
LaunchLabs – Alexandria Center, 14th Floor
430 East twenty ninth Street – New York, NY 10016 (USA)